Applied Therapeutics Reports Second Quarter 2025 Financial Results
APTH- CMT-SORD program advances; meeting scheduled with the FDA in Q3 2025 to discuss govorestat for the treatment of CMT-SORD
August 13, 2025Earnings
Read more →- CMT-SORD program advances; meeting scheduled with the FDA in Q3 2025 to discuss govorestat for the treatment of CMT-SORD